What is IgA nephropathy and how does FILSPARI treat it?

IgA nephropathy (IgAN) definition: IgA nephropathy (also called Berger's disease) is an autoimmune kidney disease in which abnormal IgA antibodies (immunoglobulin A, normally a component of mucosal immunity) deposit in the kidney's glomeruli (tiny filtering structures); these IgA deposits trigger inflammation and scarring of the glomeruli, progressively reducing kidney function; IgAN is the most common primary kidney disease worldwide, affecting approximately 150,000 diagnosed patients in the U.S.; IgAN often develops in young adults (20s-40s) and can progress to end-stage kidney disease requiring dialysis or transplant over 10-20 years. Proteinuria as a marker: proteinuria (protein leakage into urine) is the key marker of IgAN disease activity; healthy kidneys retain protein in the blood; diseased glomeruli leak protein into urine; higher proteinuria levels correlate with faster disease progression and worse outcomes; clinical trials for IgAN treatments measure proteinuria reduction as a surrogate endpoint for kidney protection. FILSPARI's mechanism: FILSPARI (sparsentan) is the first dual endothelin receptor (ETA/ETB) and angiotensin II (AT1) receptor antagonist approved for kidney disease; endothelin-1 and angiotensin II are vasoconstrictive hormones that constrict the blood vessels and capillaries of the kidney's filtration units; blocking both receptors simultaneously reduces intraglomerular pressure (pressure within the kidney's filtering structures), reduces inflammation, and reduces proteinuria more robustly than blocking either receptor alone; the dual blockade is the key differentiation from ACE inhibitors or ARBs (angiotensin blockers alone) that are standard of care for IgAN. Diagnosis challenge: IgAN can only be definitively diagnosed by kidney biopsy — a procedure where a needle is inserted into the kidney under ultrasound guidance to extract a small tissue sample for pathological analysis; kidney biopsy is invasive (with a small risk of bleeding and complications) and not performed routinely; many patients with early IgAN have not had biopsies and are thus undiagnosed; expanding FILSPARI's addressable market requires increasing IgAN diagnosis rates, which requires physician education about when to consider biopsy for patients with proteinuria and hematuria (blood in urine).

What is the complement system and why is blocking C3 (versus C5) potentially advantageous?

Complement system overview: the complement system is a network of approximately 30+ proteins that are part of the innate immune system; complement proteins circulate in the blood in inactive forms and are activated in a cascade (like dominoes) in response to foreign pathogens, damaged cells, or immune complexes; when activated, complement proteins: tag foreign cells for destruction (opsonization), directly destroy bacteria (membrane attack complex), and recruit inflammatory cells to infection sites; complement dysfunction causes diseases when complement activates inappropriately against the body's own cells. Complement cascade structure: the complement cascade has three activation pathways (classical, lectin, and alternative pathways) that all converge at C3; C3 is the central hub — all three pathways activate C3; activated C3 then generates C3a (inflammatory signaling) and C3b (opsonization — tagging cells for destruction); downstream of C3, the cascade continues to C5, then C5a (more inflammation) and C5b-9 (membrane attack complex — directly punches holes in cell membranes). C5 inhibition (eculizumab/ravulizumab mechanism): the first generation of complement inhibitors (Alexion's eculizumab/Soliris, ravulizumab/Ultomiris) block C5, preventing the terminal complement pathway (membrane attack complex and C5a inflammation); these drugs are highly effective for PNH (preventing red blood cell destruction by the membrane attack complex) but do not prevent all complement effects since C3a signaling still occurs. C3 inhibition (Apellis's pegcetacoplan mechanism): by blocking C3, Apellis's approach prevents all downstream complement activation — both the C5-terminal pathway AND the C3a inflammatory signaling; theoretically, C3 inhibition provides more complete complement suppression than C5 inhibition; in practice, C3 inhibition may reduce certain inflammatory signals that C5 inhibitors miss, which could provide advantages in diseases where C3a-driven inflammation is important (like geographic atrophy, where drusen contain C3 fragments and C3a drives chronic macular inflammation). Trade-off: C3 inhibition is more 'upstream' and therefore potentially more broadly suppressive of complement — which could be advantageous in complement-driven diseases but also raises theoretical concerns about excessive immune suppression (complement is an important defense against certain bacteria like Neisseria meningitidis, requiring patients on C3 inhibitors to receive meningococcal vaccination).

Why are rare disease drugs commercially valuable despite small patient populations?

Orphan drug economics: a drug that treats a rare disease (affecting fewer than 200,000 U.S. patients) can earn 'orphan drug designation' from the FDA; orphan drugs receive 7 years of market exclusivity after approval (preventing generic competition for a longer period than standard drugs' 5-year data exclusivity), tax credits for clinical development costs (25% of qualified clinical testing expenses), waived FDA user fees (saving $3-5 million per review), and expedited review designation; these economic benefits partially compensate for the small patient population. Pricing power: rare disease drugs typically carry premium pricing because: the patient population is small (fixed clinical development costs must be amortized over fewer patients, requiring higher price per patient); the diseases are serious (often life-threatening or severely debilitating), creating strong physician and patient willingness to pay; payers (insurers) have limited ability to exclude coverage for serious, rare conditions with no alternatives; regulatory data exclusivity limits generic competition for years. Commercial efficiency: a rare disease company selling a drug at $200,000-500,000/year per patient doesn't need to sign up millions of patients to generate substantial revenue; a drug for a 50,000-patient market at $150,000/year per patient generates $7.5 billion in peak sales if fully penetrated — larger than many blockbuster drugs for common conditions at $5-15/day; commercial infrastructure (sales force size, marketing) can be much smaller for a rare disease with a well-defined specialist physician community vs. a common disease requiring primary care physician marketing. Unmet need premium: for diseases with no prior treatment (geographic atrophy before SYFOVRE, IgAN before FILSPARI), there is no price comparison anchor; payers must weigh the cost of the new drug against the cost of disease progression (dialysis for IgAN patients, vision loss and its associated costs for GA patients); this unmet need context supports premium pricing that would not be possible if generic alternatives existed.

brimindinvest.com / compare / apls-vs-retaLIVE

APLS

Apellis Pharmaceuticals, Inc. · Healthcare - Specialty Biopharmaceuticals (Complement Biology)

$41.03

+0.45% this month

VERSUS

⟷

COMPARE

TVTX

Travere Therapeutics, Inc. · Healthcare - Rare Renal and Metabolic Disease Biopharmaceuticals

$55.15

+30.50% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

APLS

1

TVTX

3

TVTX LEADS 3/5

Comparison scoreboard

TVTX LEADS 3/5

AI Score

APLS 41.0

TVTX ✓46.5

1Y Return

APLS +150.79%

TVTX ✓+282.72%

Fwd P/E

APLS ✓-130.55

TVTX 11.36

Target Up.

APLS -0.26%

TVTX ✓+3.87%

Op. Margin

APLS N/A

TVTX N/A

Metrics last refreshed: 6/22/2026

Quick take

APLS vs TVTX Stock Comparison: AI Score, Valuation, Performance and Upside

APLS (Apellis Pharmaceuticals) and TVTX (Travere Therapeutics) are both rare disease biopharmaceuticals that achieved first approvals for diseases with significant unmet needs — Apellis's SYFOVRE targeting geographic atrophy (dry AMD progression) with C3 complement inhibition, and Travere's FILSPARI targeting IgA nephropathy (kidney disease) with dual endothelin/angiotensin receptor blockade — both facing competitive dynamics as additional drugs enter previously underserved markets.

APLS vs TVTX is complement biology pioneer with geographic atrophy first approval and multi-disease platform ambitions (Apellis's SYFOVRE large GA market opportunity, C3 inhibition pipeline, and PNH EMPAVELI revenue — retinal vasculitis safety concerns, IZERVAY competition, and slower-than-expected commercial ramp) versus rare renal disease company with IgAN first approval and FSGS expansion potential (Travere's FILSPARI kidney disease leadership, dual receptor mechanism differentiation, and orphan drug exclusivity — competitive IgAN market, kidney biopsy diagnosis barriers, and limited capital resources).

Live analysis · updated 6/22/2026

TVTX holds the edge across 3 of 5 key metrics in this comparison. TVTX has delivered stronger 1-year price return (+282.72% vs +150.79%), though APLS trades at the lower forward P/E (-130.55x vs 11.36x). Analyst consensus implies meaningfully more upside for TVTX (+3.87%) than for APLS (-0.26%).

Normalized 1Y performance

APLS

TVTX

Recent returns

APLS

TVTX

Analyst price targets & sentiment

APLS · 13 analysts

STRONG BUYHOLDSTRONG SELL

Hold (2.9/5.0)

Price target range

analyst low$40.00
analyst high$41.00
analyst mean$40.92
current price$41.03

-0.3% upside to analyst mean

TVTX · 14 analysts

STRONG BUYHOLDSTRONG SELL

Strong Buy (1.3/5.0)

Price target range

analyst low$43.00
analyst high$70.00
analyst mean$57.29
current price$55.15

+3.9% upside to analyst mean

Who should consider this stock?

APLS may suit investors who:

→Want ophthalmology biopharmaceutical exposure through SYFOVRE as the first approved treatment for geographic atrophy — a condition affecting 1 million Americans with irreversible central vision loss that had no prior approved therapy
→Value Apellis's complement biology platform as potentially applicable to multiple complement-driven diseases beyond GA and PNH, creating pipeline optionality beyond the current commercial portfolio
→Accept the commercial ramp risk of a first-in-class treatment requiring patient diagnosis, physician training, and formulary access in a competitive landscape where IZERVAY also targets GA

TVTX may suit investors who:

→Want rare kidney disease biopharmaceutical exposure through FILSPARI as the first dual-mechanism disease-modifying treatment for IgA nephropathy — the most common primary kidney disease with previously limited treatment options
→Value Travere's orphan drug status providing market exclusivity and regulatory benefits in IgAN and potentially FSGS indications that protect the commercial window
→Accept competition from multiple approved and developing IgAN treatments for the potential of FILSPARI's dual endothelin/angiotensin blockade providing superior or differentiated efficacy in a growing rare kidney disease market

Performance & AI score

Metric	APLS	TVTX
AI score	41.0	46.5
AI rank	#997	#664
Latest close	$41.03	$55.15
1M return	+0.45%	+30.50%
6M return	+107.12%	+62.73%
1Y return	+150.79%	+282.72%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	APLS	TVTX
1Y ago	$25.08K (+150.8%) started 2025-05-15	$38.27K (+282.7%) started 2025-06-18
5Y ago	$7.73K (-22.7%) started 2021-05-17	$34.82K (+248.2%) started 2021-06-18
10Y ago	$29.24K (+192.4%) started 2017-11-09	$31.42K (+214.2%) started 2016-06-20

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	APLS	TVTX
Market cap	$5.25B	$5.13B
Trailing P/E	38.35	N/A
Forward P/E	-130.55	11.36
Price/Sales	4.75	9.56
EV/Revenue	4.82	9.68
Analyst target	$40.92	$57.29
Target upside	-0.26%	+3.87%

Growth, profitability & risk

Metric	APLS	TVTX
Revenue growth	60.90%	55.60%
Earnings growth	N/A	N/A
EPS growth	N/A	N/A
FCF margin	-5.76%	-9.54%
Operating margin	N/A	N/A
Profit margin	12.06%	-4.00%
ROIC proxy	46.02%	-69.38%
Return on equity	46.02%	-69.38%
Dividend yield	N/A	0.00%
Beta	-0.25	1.14
Debt/equity	114.66	331.88
Current ratio	3.63	3.13
Quick ratio	3.00	2.82

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

APLS max drawdown43.53%

TVTX max drawdown33.49%

APLS max wkly drop33.61%

TVTX max wkly drop20.26%

5Y risk snapshot

APLS max drawdown82.47%

TVTX max drawdown83.12%

APLS max wkly drop60.18%

TVTX max wkly drop44.60%

10Y risk snapshot

APLS max drawdown82.47%

TVTX max drawdown83.64%

APLS max wkly drop60.18%

TVTX max wkly drop44.60%

Performance metrics by period

Period	Metric	APLS	TVTX
1Y	Growth	+150.79%	+282.72%
	CAGR	+150.95%	+283.07%
	Sharpe ratio	1.06	2.15
	Max drawdown	43.53%	33.49%
	Max daily drop	31.01%	14.63%
	Max wkly drop	33.61%	20.26%
5Y	Growth	-22.67%	+248.17%
	CAGR	-5.02%	+28.34%
	Sharpe ratio	0.27	0.65
	Max drawdown	82.47%	83.12%
	Max daily drop	37.92%	40.68%
	Max wkly drop	60.18%	44.60%
10Y	Growth	+192.44%	+214.25%
	CAGR	+13.44%	+12.14%
	Sharpe ratio	0.46	0.42
	Max drawdown	82.47%	83.64%
	Max daily drop	37.92%	40.68%
	Max wkly drop	60.18%	44.60%

Business comparison

Category	APLS	TVTX
Company	Apellis Pharmaceuticals, Inc.	Travere Therapeutics, Inc.
Sector	Healthcare - Specialty Biopharmaceuticals (Complement Biology)	Healthcare - Rare Renal and Metabolic Disease Biopharmaceuticals
Industry	N/A	N/A
Core business	Apellis Pharmaceuticals is a biopharmaceutical company pioneering C3 complement inhibition — blocking a protein (C3) at the central 'hub' of the complement system, an immune pathway that drives inflammation and tissue destruction in multiple diseases. Apellis's lead drugs include: SYFOVRE (pegcetacoplan intravitreal injection) — approved for geographic atrophy (GA), a late-stage dry AMD condition that causes progressive, irreversible central vision loss with no prior approved treatments; EMPAVELI (pegcetacoplan subcutaneous injection) — approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder in which complement destroys red blood cells; and a pipeline targeting additional complement-driven diseases. SYFOVRE's approval in 2023 addressed one of the largest unmet needs in ophthalmology.	Travere Therapeutics (formerly Retrophin, renamed following strategic repositioning) is a biopharmaceutical company focused on rare renal (kidney) and metabolic diseases. Travere's lead product is FILSPARI (sparsentan) — approved by the FDA in 2023 for IgA nephropathy (IgAN, also called Berger's disease), the most common primary kidney disease globally; IgAN causes progressive kidney function decline; FILSPARI is a dual endothelin receptor/angiotensin II receptor antagonist that reduces proteinuria (protein leakage in urine — a measure of kidney damage) and slows disease progression. Travere also has cystinuria programs (orphan diseases affecting amino acid metabolism causing kidney stones). The company also has sparsentan in development for focal segmental glomerulosclerosis (FSGS), another serious kidney disease.
Investor focus	Investors track SYFOVRE's commercial ramp in geographic atrophy (prescription volume, market penetration, formulary access), EMPAVELI's PNH market share, and pipeline advancement of pegcetacoplan or next-generation molecules into additional complement-driven diseases.	Investors track FILSPARI's prescription growth for IgAN, formulary coverage (payer access), the renal biopsy/diagnosis rate for IgAN (limiting patient identification), FSGS pivotal trial data, and the competitive landscape as more IgAN treatments are approved.

APLS strengths

→SYFOVRE addresses geographic atrophy — a large unmet medical need with no prior approved treatments; GA affects approximately 1 million Americans and causes irreversible central vision loss; SYFOVRE's approval opened a new market that no prior drug served
→Complement system is implicated in many diseases beyond GA and PNH; Apellis's pipeline explores additional complement-driven conditions, potentially expanding the commercial opportunity
→C3 inhibition offers theoretically superior complement blockade by targeting the central complement hub rather than downstream targets; this could provide efficacy advantages over complement inhibitors targeting C5 (like eculizumab)

TVTX strengths

→FILSPARI addresses IgAN — a large rare kidney disease with significant unmet need; IgAN affects approximately 150,000 diagnosed patients in the U.S. (with many undiagnosed); before FILSPARI, limited disease-modifying treatment options existed beyond angiotensin blockade
→Dual mechanism of action (dual blockade of endothelin and angiotensin receptors) differentiates FILSPARI from single-mechanism alternatives; clinical data showed robust proteinuria reduction
→Orphan drug designation provides market exclusivity (7 years for rare diseases) and regulatory benefits that protect FILSPARI's commercial position in IgAN and potential FSGS indication

Risks to watch — APLS

→SYFOVRE commercial execution challenges — geographic atrophy treatment requires patients to receive intravitreal (into the eye) injections every 25-60 days; physician adoption requires training and workflow integration; early commercial ramp was slower than initial expectations
→Apellis faced a serious adverse event concern in 2023 when retinal vasculitis (inflammation of retinal blood vessels) occurred in some SYFOVRE-treated patients; FDA label updates and risk communication added complexity to the commercial launch
→Competition from Iveric Bio's avacincaptad pegol (IZERVAY, approved by FDA after a Astellas acquisition) — IZERVAY is a C5 complement inhibitor for geographic atrophy that competes directly with SYFOVRE; two GA drugs now compete for the same patient population

Risks to watch — TVTX

→IgAN competitive market is rapidly evolving — multiple drugs have been approved or are in late-stage development for IgAN: Calliditas Therapeutics's Tarpeyo (budesonide), Chinook/Novartis's atrasentan; competition reduces FILSPARI's market opportunity
→IgAN diagnosis requires kidney biopsy, which limits patient identification — many IgAN patients are undiagnosed because kidney biopsy (the definitive diagnostic test) is an invasive procedure; increasing diagnosis rates requires physician education
→Travere has limited financial resources compared to larger pharma competitors; commercializing FILSPARI while funding the FSGS trial requires careful capital management; dilutive financings could be needed

Frequently asked questions

Geographic atrophy (GA) definition: geographic atrophy is the advanced stage of dry age-related macular degeneration (AMD) — the leading cause of blindness in Americans over 60; the macula (the central portion of the retina responsible for detailed central vision) progressively loses photoreceptor cells in GA; vision loss is permanent as photoreceptors cannot regenerate; GA affects approximately 1 million Americans and causes loss of reading ability, face recognition, and other fine-detail vision; before SYFOVRE, there were no FDA-approved treatments that slowed GA progression. Complement system role in GA: the complement system is an immune defense network that normally tags foreign cells for destruction; in GA, complement becomes chronically activated in the aging macula, causing 'bystander destruction' of photoreceptor cells; complement proteins (particularly C3) accumulate in drusen (deposits under the retina) that characterize AMD; chronic complement activation drives the progressive photoreceptor cell death that defines GA. SYFOVRE mechanism: SYFOVRE (pegcetacoplan) is a complement C3 inhibitor — it binds to C3 protein and prevents it from being cleaved into its active forms (C3a and C3b); by blocking C3 at this central hub, SYFOVRE interrupts the complement activation cascade before it can activate downstream complement effectors that damage photoreceptors; this addresses the root cause of complement-driven photoreceptor destruction. Clinical results: in the DERBY and OAKS trials, SYFOVRE reduced the rate of GA lesion growth by approximately 20% compared to sham injections over 12 months — meaning GA still progressed, but more slowly; the slowing of progression delays visual impairment for patients; for a disease with no prior treatment, slowing progression by 20% represented a meaningful benefit. Administration: SYFOVRE is administered as an intravitreal injection (into the vitreous humor of the eye) by a retina specialist; injections are initially monthly, potentially extended to every other month based on patient response; the need for repeated eye injections is a patient adherence and physician workflow challenge.

AI Prediction SignalNext 5 trading days

Members only

APLS

+2.8%BUY

TVTX

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides